PPAR{gamma} Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue

Blocking phosphorylation of peroxisome proliferator–activated receptor (PPAR) at Ser273 is one of the key mechanisms for antidiabetes drugs to target PPAR. Using high-throughput phosphorylation screening, we here describe that Gleevec blocks cyclin-dependent kinase 5–mediated PPAR phosphorylation devoid of classical agonism as a PPAR antagonist ligand. In high fat–fed mice, Gleevec improved insulin sensitivity without causing severe side effects associated with other PPAR-targeting drugs. Furthermore, Gleevec reduces lipogenic and gluconeogenic gene expression in liver and ameliorates inflammation in adipose tissues. Interestingly, Gleevec increases browning of white adipose tissue and energy expenditure. Taken together, the results indicate that Gleevec exhibits greater beneficial effects on both glucose/lipid metabolism and energy homeostasis by blocking PPAR phosphorylation. These data illustrate that Gleevec could be a novel therapeutic agent for use in insulin resistance and type 2 diabetes.

Diabetes Journal current issue





  • Twitter
  • del.icio.us
  • Digg
  • Facebook
  • Technorati
  • Reddit
  • Yahoo Buzz
  • StumbleUpon

Leave a Reply

Your email address will not be published. Required fields are marked *